Somatuline® Depot: chosen by over 5,800 doctors since 2017*
*Prescription data based on IQVIA insurance claims for NETs during November 2017–October 2020 Q3, subject to change without notice.
In clinical studies, Somatuline Depot reduced the risk of disease progression or death by 53% versus placebo. At 22 months, more than half of the patients taking Somatuline Depot did not have their cancer progress. For those taking placebo, it took 16.6 months until half the patients had their cancer progress.
About the study
Somatuline Depot was studied for nearly 2 years in 204 adult patients with various types of GEP-NETs that had spread or could not be removed by surgery. In some patients, the cancer started in their pancreas. In others, it started in a different place, such as their intestinal tract, which includes the colon.
Patients in the study were divided into 2 groups, which received either Somatuline Depot 120 mg or placebo by deep subcutaneous injection every 4 weeks. The primary goal of this study was to determine if Somatuline Depot improved progression-free survival, which is the amount of time it took for the disease to progress.
FDA-approved to treat adults with carcinoid syndrome to reduce the need for the use of short-acting somatostatin medicine
Short-acting medicines are used to lessen symptoms of carcinoid syndrome, including diarrhea and flushing. Somatuline Depot was shown to reduce the use of short-acting medicines by 15%.
About the study
Somatuline Depot was studied for 16 weeks in 115 patients with confirmed NETs and a history of carcinoid syndrome (flushing and/or diarrhea) to reduce the need for use of short-acting somatostatin medicine.
Patients were divided into 2 groups, which received either Somatuline Depot 120 mg or placebo by deep subcutaneous injection every 4 weeks. Many patients were living with carcinoid syndrome as a result of being diagnosed with NETs for less than a year before starting treatment.
Common side effects
For people with carcinoid syndrome, the most common side effects were: headache, dizziness, and muscle spasm. Side effects for carcinoid syndrome were generally similar to those commonly seen in the GEP-NETs trial.
It’s important to know what side effects are commonly associated with Somatuline Depot, so you can discuss them with your medical team.